Pharmacogenetics of outcome in children with acute lymphoblastic leukemia.

Acquired genetic characteristics of acute lymphoblastic leukemia (ALL) cells are used to individualize therapy, whereas germ line genetic characteristics generally are not. We determined whether ALL outcome was related to 16 genetic polymorphisms affecting the pharmacodynamics of antileukemic agents. Of 246 children, 116 were treated on the lower-risk (LR) and 130 on the higher-risk (HR) arms of a St Jude protocol. Patients in the HR group with the glutathione S-transferase (GSTM1) non-null genotype had greater risk of hematologic relapse (P = .03), which was further increased by the thymidylate synthetase (TYMS) 3/3 genotype (P = .03). These genotypes remained predictive in multivariate analyses (P < .001 and .003, respectively). No genotypes were predictive in the LR arm. Expression of these 2 genes in ALL blasts was lower in those with low-activity genotypes. For central nervous system relapse, among the HR group, the vitamin D receptor start site (P = .02) and intron 8 genotypes (P = .04) predisposed, whereas for LR patients the TYMS 3/3 genotype predisposed (P = .04). The GSTM1 non-null and TYMS 3/3 genotypes are plausibly linked to drug resistance. Polymorphisms interact to influence antileukemic outcome and represent determinants of response that can be used to optimize therapy.

[1]  M. Relling,et al.  Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemia. , 2009, NCI monographs : a publication of the National Cancer Institute.

[2]  Cheng Cheng,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. , 2004, Blood.

[3]  W. Kern,et al.  Satelite Symposium V, Meet-the-Professor Sessions I and II, Main Sessions I-IX , 2004, Annals of Hematology.

[4]  D. Townsend,et al.  The role of glutathione-S-transferase in anti-cancer drug resistance , 2003, Oncogene.

[5]  K. Ness,et al.  Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. , 2003, JAMA.

[6]  J. Downing,et al.  Results of therapy for acute lymphoblastic leukemia in black and white children. , 2003, JAMA.

[7]  E. Cook,et al.  Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Relling,et al.  Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. , 2003, The New England journal of medicine.

[9]  F. Behm,et al.  Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. , 2003, Blood.

[10]  M. Nakajima,et al.  Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[11]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[12]  R. Weinshilboum.  Inheritance and drug response. , 2003, The New England journal of medicine.

[13]  F. Behm,et al.  Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. , 2002, Pharmacogenetics.

[14]  L. Robison,et al.  Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. , 2002, Blood.

[15]  C. Pui,et al.  Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region , 2002, The Lancet.

[16]  M. Krajinovic,et al.  Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia , 2002, The Lancet.

[17]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[18]  D. Labuda,et al.  Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  E. Oren,et al.  Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. , 2001, JAMA.

[20]  S. Marsh,et al.  Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. , 2001, Cancer research.

[21]  J H Eckfeldt,et al.  The 1298A-->C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. , 2001, Atherosclerosis.

[22]  J. Eisman,et al.  Pharmacogenetics of the vitamin D receptor and osteoporosis. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[23]  J. García-Foncillas,et al.  Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Gelber,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. , 2001, Blood.

[25]  F. Behm,et al.  Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. , 2000, Blood.

[26]  W. Hiddemann,et al.  Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. , 2000, Blood.

[27]  M. Schrappe,et al.  Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. , 2000, Blood.

[28]  J. Shuster,et al.  Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[30]  M. Relling,et al.  Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. , 1999, Blood.

[31]  M. Relling,et al.  Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. , 1998, The New England journal of medicine.

[32]  P. Watkins,et al.  Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. , 1997, Molecular pharmacology.

[33]  Ching-Hon Pui,et al.  Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance , 1997, Annals of Internal Medicine.

[34]  M. Relling,et al.  Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia , 1997 .

[35]  M. Ratain,et al.  Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. , 1997, Journal of the National Cancer Institute.

[36]  B. Camitta,et al.  Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Eisman,et al.  Prediction of bone density from vitamin D receptor alleles , 1994, Nature.

[38]  R. Weinshilboum,et al.  Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia , 1990, The Lancet.

[39]  S L George,et al.  Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. , 1986, The New England journal of medicine.

[40]  E. Cook,et al.  Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. , 2004, Blood.

[41]  M. Schrappe,et al.  Thymidylate synthase gene polymorphism and its association with relapse in childhood B-cell precursor acute lymphoblastic leukemia. , 2003, Haematologica.

[42]  W. Tissing,et al.  Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia , 2003, Leukemia.

[43]  E. Schuetz,et al.  Transcriptional Control of Intestinal Cytochrome P-4503A by 1 (cid:1) ,25-Dihydroxy Vitamin D 3 , 2001 .

[44]  Ames,et al.  Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent. , 1997, The New England journal of medicine.

[45]  D. Grobbee,et al.  A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. , 1998, The Journal of clinical endocrinology and metabolism.

[46]  M. Relling,et al.  Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. , 1997, Blood.

[47]  G. Mickisch.  Multidrug Resistance , 1996, Der Urologe A.

[48]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .